Abstract | BACKGROUND: METHODS: BCCs (MCF-7 and HCC70 cells) were cultured with different concentrations of daunorubicin (DNR) (from 1x10(-9) to 1x10(-6)M) in the presence or absence of selected concentrations of MGN-3 (100-1000mug/ml) for 3 days. Cancer cell survival was determined by MTT assay and drug accumulation was determined by flow cytometry. RESULTS: Treatment with MGN-3 increased susceptibility of BCCs to DNR (5.5-fold for MCF-7 and 2.5-fold for HCC70 cells) as compared to BCCs treated with DNR alone. The sensitizing effect of MGN-3 was associated with increased accumulation of DNR in cancer cells. CONCLUSIONS: Our data demonstrate that MGN-3 is an effective chemo-sensitizer and may represent a potential novel adjuvant for the treatment of breast cancer.
|
Authors | Sastry Gollapudi, Mamdooh Ghoneum |
Journal | Cancer detection and prevention
(Cancer Detect Prev)
Vol. 32
Issue 1
Pg. 1-6
( 2008)
ISSN: 1525-1500 [Electronic] England |
PMID | 18406070
(Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antineoplastic Agents
- Xylans
- polysaccharide MGN3
- Daunorubicin
|
Topics |
- Antineoplastic Agents
(therapeutic use)
- Breast Neoplasms
(drug therapy)
- Cell Line, Tumor
- Cell Survival
- Chemotherapy, Adjuvant
- Daunorubicin
(pharmacokinetics, therapeutic use)
- Dose-Response Relationship, Drug
- Drug Synergism
- Humans
- Xylans
(therapeutic use)
|